CN100411618C - 有效的选择性阿片受体调制剂化合物的用途 - Google Patents

有效的选择性阿片受体调制剂化合物的用途 Download PDF

Info

Publication number
CN100411618C
CN100411618C CNB038111373A CN03811137A CN100411618C CN 100411618 C CN100411618 C CN 100411618C CN B038111373 A CNB038111373 A CN B038111373A CN 03811137 A CN03811137 A CN 03811137A CN 100411618 C CN100411618 C CN 100411618C
Authority
CN
China
Prior art keywords
compounds
asimadoline
purposes
phenyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038111373A
Other languages
English (en)
Chinese (zh)
Other versions
CN1655784A (zh
Inventor
F·韦伯
J·雅各布
A·巴贝尔
R·戈特施利希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN1655784A publication Critical patent/CN1655784A/zh
Application granted granted Critical
Publication of CN100411618C publication Critical patent/CN100411618C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038111373A 2002-05-17 2003-04-28 有效的选择性阿片受体调制剂化合物的用途 Expired - Fee Related CN100411618C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02011047.4 2002-05-17
EP02011047 2002-05-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2008101295692A Division CN101310723A (zh) 2002-05-17 2003-04-28 有效的选择性阿片受体调制剂化合物的用途

Publications (2)

Publication Number Publication Date
CN1655784A CN1655784A (zh) 2005-08-17
CN100411618C true CN100411618C (zh) 2008-08-20

Family

ID=29433078

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB038111373A Expired - Fee Related CN100411618C (zh) 2002-05-17 2003-04-28 有效的选择性阿片受体调制剂化合物的用途
CNA2008101295692A Pending CN101310723A (zh) 2002-05-17 2003-04-28 有效的选择性阿片受体调制剂化合物的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2008101295692A Pending CN101310723A (zh) 2002-05-17 2003-04-28 有效的选择性阿片受体调制剂化合物的用途

Country Status (20)

Country Link
US (1) US20050176746A1 (https=)
EP (2) EP2074997A1 (https=)
JP (1) JP2005531557A (https=)
KR (1) KR101108014B1 (https=)
CN (2) CN100411618C (https=)
AR (1) AR040028A1 (https=)
AT (1) ATE429226T1 (https=)
AU (1) AU2003242527B2 (https=)
BR (1) BR0309969A (https=)
CA (1) CA2486000A1 (https=)
DE (1) DE60327315D1 (https=)
DK (1) DK1505974T3 (https=)
ES (1) ES2325782T3 (https=)
MX (1) MXPA04011333A (https=)
PE (1) PE20040455A1 (https=)
PL (1) PL371596A1 (https=)
RU (1) RU2336871C2 (https=)
TW (1) TWI314053B (https=)
WO (1) WO2003097051A2 (https=)
ZA (1) ZA200410160B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10259245A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1911763B1 (en) 2003-01-28 2010-08-11 Ironwood Pharmaceuticals, Inc. Compositions for the treatment of gastrointestinal disorders
EP1870096A3 (en) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
HUE034290T2 (en) 2003-04-29 2018-02-28 Orexigen Therapeutics Inc Preparations containing opioid antagonist and bupropion to affect weight loss
EP1680115A1 (en) * 2003-10-30 2006-07-19 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
CA2630624C (en) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
CA2682608A1 (en) * 2007-03-30 2008-10-09 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20100221329A1 (en) 2008-12-03 2010-09-02 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
MX381407B (es) 2008-12-31 2025-03-12 Ardelyx Inc Compuestos y métodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrógeno (nhe) en el tratamiento de trastornos asociados con retención de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
RU2413512C1 (ru) * 2009-07-29 2011-03-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" Средство, обладающее каппа-опиоидной агонистической активностью
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
WO2012012410A2 (en) * 2010-07-19 2012-01-26 Dr. Reddy's Laboratories Ltd. Kappa opioid receptor agonists
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
LT3730132T (lt) 2012-06-06 2022-08-25 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HRP20191000T1 (hr) 2013-04-12 2019-09-20 Ardelyx, Inc. Spojevi za vezanje nhe3 i metode inhibiranja transporta fosfata
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
EA023231B1 (ru) * 2013-07-18 2016-05-31 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт нормальной физиологии имени П.К. Анохина" Российской академии медицинских наук (ФГБУ "НИИНФ им. П.К. Анохина" РАМН) Применение агониста каппа опиоидных рецепторов периферического действия ici 204,448 для приготовления средств для лечения синдрома отмены никотина
US20160250277A1 (en) * 2013-10-28 2016-09-01 Cara Therapeutics, Inc. Peripheral kappa opioid receptor agonists for preventing, inhibiting or treating nausea and vomiting
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
MX2019008171A (es) 2017-01-09 2020-02-05 Ardelyx Inc Inhibidores del antiporte mediado por nhe.
MX395405B (es) 2017-01-09 2025-03-25 Ardelyx Inc Compuestos útiles para tratar trastornos del tracto gastrointestinal.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889860A (en) * 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
WO2002013801A2 (en) * 2000-08-15 2002-02-21 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
CN1081631C (zh) * 1995-08-26 2002-03-27 默克专利股份有限公司 N－甲基－n－[(1s)－1－苯基－2－((3s)－3－羟基吡咯烷－1－基]乙基]－2,2－二苯基乙酰胺

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4034785A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
DE3935371A1 (de) 1988-12-23 1990-07-05 Merck Patent Gmbh Stickstoffhaltige ringverbindungen
US5389686A (en) * 1989-02-20 1995-02-14 Jouveinal Sa Analgesic properties of fedotozine
DE4215231C1 (en) 1992-05-09 1993-05-13 Dornier Luftfahrt Gmbh, 8031 Wessling, De Arrangement for mfg. fibre reinforced thermoplastic components - including unit for accommodating component, pressurising unit for assembled component and heating unit
DE4215213A1 (de) 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE19523502A1 (de) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
EP1021204B1 (en) * 1997-09-26 2005-12-28 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US20010051181A1 (en) * 1997-12-22 2001-12-13 Van Osdol William W. Novel formulations for the transdermal administration of asimadoline
JPH11343244A (ja) * 1998-03-30 1999-12-14 Taisho Pharmaceut Co Ltd 経口用組成物
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
HK1045528B (zh) * 1998-07-14 2006-10-27 詹森药业有限公司 神经营养生长因子
PT1033364E (pt) * 1999-03-01 2005-07-29 Pfizer Prod Inc Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide
JP2005508830A (ja) * 2000-06-19 2005-04-07 エーザイ株式会社 ピリジン誘導体を用いる方法
DE10030893A1 (de) * 2000-06-23 2002-01-03 Henkel Kgaa Paraaminophenol-Derivate und deren Verwendung
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
WO2003048113A1 (en) * 2001-11-30 2003-06-12 Sepracor Inc. Tramadol analogs and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889860A (en) * 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
CN1081631C (zh) * 1995-08-26 2002-03-27 默克专利股份有限公司 N－甲基－n－[(1s)－1－苯基－2－((3s)－3－羟基吡咯烷－1－基]乙基]－2,2－二苯基乙酰胺
WO2002013801A2 (en) * 2000-08-15 2002-02-21 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Opioid involvement in feeding behavior and the pathogenesisof certain eating disorders.. Johnson, R. D.Med.Hypotheses,Vol.45 No.5. 1995
Opioid involvement in feeding behavior and the pathogenesisof certain eating disorders.. Johnson, R. D.Med.Hypotheses,Vol.45 No.5. 1995 *
心脏恶病质综合征. 董贵红.临床荟萃，第9卷第2期. 1994
心脏恶病质综合征. 董贵红.临床荟萃，第9卷第2期. 1994 *
肿瘤恶病质机制及防治对策. 吴国豪.肠外与肠内营养，第7卷第3期. 2000
肿瘤恶病质机制及防治对策. 吴国豪.肠外与肠内营养，第7卷第3期. 2000 *
胃运动障碍. 卫好国.山西医药杂志，第17卷第1期. 1988
胃运动障碍. 卫好国.山西医药杂志，第17卷第1期. 1988 *

Also Published As

Publication number Publication date
BR0309969A (pt) 2005-04-26
ZA200410160B (en) 2005-12-28
KR101108014B1 (ko) 2012-01-25
MXPA04011333A (es) 2005-02-14
DE60327315D1 (de) 2009-06-04
RU2004137091A (ru) 2005-09-10
AR040028A1 (es) 2005-03-09
ES2325782T3 (es) 2009-09-17
EP2074997A1 (en) 2009-07-01
EP1505974A2 (en) 2005-02-16
AU2003242527B2 (en) 2008-10-23
CN101310723A (zh) 2008-11-26
PE20040455A1 (es) 2004-08-07
TWI314053B (en) 2009-09-01
EP1505974B1 (en) 2009-04-22
US20050176746A1 (en) 2005-08-11
PL371596A1 (en) 2005-06-27
TW200307541A (en) 2003-12-16
WO2003097051A3 (en) 2004-12-09
ATE429226T1 (de) 2009-05-15
AU2003242527A1 (en) 2003-12-02
DK1505974T3 (da) 2009-08-17
JP2005531557A (ja) 2005-10-20
HK1079451A1 (zh) 2006-04-07
CA2486000A1 (en) 2003-11-27
KR20050010807A (ko) 2005-01-28
CN1655784A (zh) 2005-08-17
RU2336871C2 (ru) 2008-10-27
WO2003097051A2 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
CN100411618C (zh) 有效的选择性阿片受体调制剂化合物的用途
KR101868991B1 (ko) 피라졸 유도체 및 그 의약용도
KR20220127832A (ko) 근위축성 측삭 경화증 및 관련 장애의 치료
Igarashi et al. Predictability of clinical adverse reactions of drugs by general pharmacology studies
Caccia N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed
JP3074519B2 (ja) 腸液吸収促進剤
JP2019517459A (ja) 心不全患者におけるｌｉｋ０６６の使用
JP2014507475A (ja) シクロベンザプリンを使用してうつ病を処置するための方法および組成物
JP6991315B2 (ja) サルコペニアの予防剤及び治療剤
TWI710372B (zh) 用於胃輕癱之5-ht4受體激動劑
JP2026506102A (ja) 疼痛緩和に有用なレジメンおよび組成物
KR20240006600A (ko) 투약 요법
HK1079451B (en) Use of compounds that are effective as selective opiate receptor modulators
CN116887822A (zh) 治疗软骨发育不全的方法
US20240100069A1 (en) Methods and Compositions for Treating Amyotrophic Lateral Sclerosis
JP2814892B2 (ja) 消化管運動抑制剤
HK40081935A (en) Treatment of amyotrophic lateral sclerosis
WO2021172462A1 (ja) 術後の消化管の回復促進のための医薬組成物および方法
BR112021012584A2 (pt) Composições de domperidona e métodos para tratamento de depressão
BSPh et al. Veterinary compounding for myasthenia gravis
Mancano New drugs of 2012, part I
JP2019043900A (ja) ラクツロースを有効成分とする便秘症治療剤
NZ614725B2 (en) Methods and compositions for treating depression using cyclobenzaprine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1079451

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: DIOGA PHARMACEUTICAL COMPANY

Free format text: FORMER OWNER: MERCK PATENT GMBH

Effective date: 20070727

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20070727

Address after: American California

Applicant after: Merck Patent GmbH

Address before: Darmstadt

Applicant before: Merck Patent GmbH

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1079451

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080820

Termination date: 20140428